Neoadjuvant androgen deprivation therapy through intense inhibition of the androgen target: “Midsummer Night’s Dream” or “Much Ado About Nothing”?

In the last two decades, the risk profile of patients treated with radical prostatectomy (RP) shifted away from the most favorable disease towards intermediate and high-risk diseases (1). These patients are at increased risk of recurrence and prostate cancer (PCa) mortality (2,3). From this perspective, the development of novel multimodality strategies to improve outcomes of surgically-treated PCa patients are needed.